Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Share Market News
Why the Bionomics share price is up 40% today
Warning: These are the 10 worst small-cap shares of FY 2019
Why the Bionomics share price crashed 37.5% lower today
Why Altura Mining, Appen, Bionomics, & Newcrest shares climbed higher today
Why Bionomics, Nearmap, & Splitit shares have smashed the market in 2019
Why the Bionomics share price has rebounded 75% in 2019
Share Market News
Why Altium, Bingo, Bionomics, & IOOF shares zoomed higher today
Why Automotive Holdings, Bionomics, Breville, & GWA shares stormed higher today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
|28 Jan 2022||$0.09||$0.00||0.00%||1,652,568||$0.09||$0.09||$0.09|
|27 Jan 2022||$0.09||$-0.01||-10.42%||4,121,571||$0.09||$0.10||$0.09|
|25 Jan 2022||$0.10||$0.00||0.00%||1,304,545||$0.10||$0.10||$0.09|
|24 Jan 2022||$0.10||$0.00||0.00%||3,456,699||$0.10||$0.10||$0.10|
|21 Jan 2022||$0.10||$-0.01||-9.09%||3,853,044||$0.11||$0.11||$0.10|
|20 Jan 2022||$0.11||$-0.01||-8.70%||2,055,011||$0.12||$0.12||$0.11|
|19 Jan 2022||$0.12||$0.01||9.09%||807,532||$0.12||$0.12||$0.12|
|18 Jan 2022||$0.11||$0.01||9.52%||713,480||$0.11||$0.12||$0.11|
|17 Jan 2022||$0.11||$0.00||0.00%||1,500,689||$0.11||$0.12||$0.11|
|14 Jan 2022||$0.11||$0.00||0.00%||367,239||$0.11||$0.11||$0.10|
|13 Jan 2022||$0.10||$0.00||0.00%||1,038,212||$0.11||$0.11||$0.10|
|12 Jan 2022||$0.10||$0.00||0.00%||2,394,572||$0.10||$0.11||$0.09|
|11 Jan 2022||$0.10||$0.00||0.00%||1,176,232||$0.10||$0.10||$0.10|
|10 Jan 2022||$0.10||$0.00||0.00%||460,927||$0.10||$0.10||$0.10|
|07 Jan 2022||$0.10||$0.00||0.00%||331,405||$0.10||$0.10||$0.10|
|06 Jan 2022||$0.10||$-0.01||-9.52%||3,614,723||$0.11||$0.11||$0.10|
|05 Jan 2022||$0.11||$-0.01||-9.09%||344,233||$0.11||$0.11||$0.11|
|04 Jan 2022||$0.11||$0.00||0.00%||1,384,704||$0.11||$0.11||$0.11|
|31 Dec 2021||$0.11||$-0.01||-8.70%||254,096||$0.11||$0.11||$0.11|
|30 Dec 2021||$0.12||$0.01||9.09%||47,403||$0.11||$0.12||$0.11|
|22 Dec 2021||Errol De Souza||Issued||61||$7,039,928||
Issue of options. AS per announcement on 22/12/2021.
|20 Dec 2021||Alan Fisher||Buy||100||$12,000||
|08 Apr 2021||David Wilson||Issued||35||$5,218||
|Mr Alan David Fisher||Non-Executive Director||Sep 2016||
Mr Fisher is an experienced corporate advisor and public company director. He has a track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice.
|Mr Aaron Weaver||Non-Executive Director||Jul 2020||
Mr Weaver is a Principal at Apeiron Investments Group Ltd ("Apeiron"), focused on the life sciences and technology sector. From 2013 - 2017, he was an investment banker at Credit Suisse Group AG in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 - 2013. Mr Weaver currently serves on the board of Bionomics as Apeiron's nominee. He is a Chartered Financial Analyst ("CFA") and a registered solicitor in the United Kingdom. He is also a director at MagForce AG, LEAF4Life LLC, Alto Neuroscience, Endogena Therapeutics, Inc., Rejuveron Life Sciences AG.
|Dr Errol B De Souza||Executive ChairmanExecutive Director||Aug 2016||
Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He has experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences Inc.) and served as President and CEO of several public (Biodel Inc.; Synaptic Pharmaceutical Corp.) and private (Archemix Corp. and Neuropore Therapies Inc.) biotech companies. Dr De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr De Souza's career, he has served in a number of high-ranking R&D roles, including SVP and US Head of R&D for Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992). Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences, Inc. (CBIO), Cyclerion Therapeutics (CYCN) and Royalty Pharma plc (RPRX). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP
|Mr David Ian Wilson||Non-Executive Director||Jun 2016||
Mr Wilson is Chairman and founding partner of WG Partners and has over 30 years experience in investment banking in the City of London. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson was previously Senior Independent Director of Optos plc prior to its successful sale of Nikon Corporation for approximately $400m as well as a Non-Executive Director of BerGenBio AS.
|Dr Jane Ryan||Non-Executive Director||Sep 2020||
Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives including the awarding of a $230m US Government contract.
|Mr Peter Miles Winston Davies||Non-Executive Director||Jul 2021||
Mr Davies has a 15-year of experience in the financial services industry with multi-sector and multifunction knowledge. He has experience in advising private and public company Board of Directors and shareholders of businesses. He has completed numerous M&A transactions across a range of sectors including healthcare, along with experience in capital raising and restructuring opportunities during his time at Rothschild & Co. Mr Davies is currently an Investment Professional at Apeiron Investments Group and is Chief Business Officer for Leaf4Life Inc.
|Ms Suzanne Grace Irwin||Company Secretary||Apr 2021||
|Mr Adrian Hinton||Chief Financial Officer||
|Suzanne Grace Irwin||Company Secretary||
|Ms Liz Doolin||Vice President Clinical Development||
|Mr Connor Bernstein||Vice President Strategy and Corporate Development||
|HSBC Custody Nominees (Australia) Limited||312,436,400||30.95%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||74,485,740||7.38%|
|BNP Paribas Noms Pty Ltd (Drp)||41,275,177||4.09%|
|Us Register Control A/C\C||34,208,416||3.39%|
|Bell Potter Nominees Ltd (Bb Nominees A/C)||28,472,814||2.82%|
|HSBC Custody Nominees (Australia) Limited (Gsco Customers A/C)||21,460,207||2.13%|
|BNP Paribas Nominees Pty Ltd Berenberg Omx Client B2B (Drp A/C)||19,781,386||1.96%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd (Drp A/C)||19,458,692||1.93%|
|Forward Vision Vii Lp Series 2||19,378,501||1.92%|
|Merrill Lynch (Australia) Nominees Pty Limited||18,101,438||1.79%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd (Drp A/C)||17,945,687||1.78%|
|Citicorp Nominees Pty Limited||17,699,930||1.75%|
|Cs Fourth Nominees Pty Limited (HSBC Cust Nom Au Ltd 11 A/C)||15,467,564||1.53%|
|Mr Jason Howard David Camm||9,102,132||0.90%|
|L&M Group Limited||8,884,085||0.88%|
|National Nominees Limited (Db A/C)||8,655,315||0.86%|
|Lifesci Venture Partners Ii Lp||7,995,000||0.79%|
|Ambria Investors Lp||4,845,050||0.48%|
|Welas Pty Ltd (The Wales Family Super A/C)||4,403,719||0.44%|
|Qualvest Pty Ltd (Lin Super Fund A/C)||4,000,000||0.40%|